Tyrosine kinase inhibitors after progression on atezolizumab-bevacizumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis
World Journal of Hepatology · 27.06.2026 · 18 (6)
DOI: 10.4254/wjh.121656 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift World Journal of Hepatology, online erschienen am 27.06.2026. Verfasst von Ronald Blanco Montecino und 7 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Atezolizumab (ATE) plus bevacizumab (BEV) is the standard first-line therapy for patients with unresectable hepatocellular carcinoma (HCC). However, the optimal second-line treatment after disease progression remains undefined. Tyrosine kinase inhibitors (TKI) established in the pre-immunotherapy era are commonly used, but their efficacy and safety following prior immunotherapy exposure are not well characterized. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of TKIs in patients with advanced HCC after progression on ATE plus BEV. AIM To evaluate efficacy and safety of TKIs after progression on ATE-BEV in advanced HCC. METHODS We conducted a systematic review and meta-analysis of studies evaluating TKIs after progression on ATE-BEV. PubMed, Scopus, Web of Science, and Cochrane Central were searched from inception to October 27, 2024. Eligible studies included retrospective or prospective cohorts, case series, and clinical trials reporting survival, radiologic response, or adverse events. Pooled means and proportions were calculated using random-effects models. Risk of bias was assessed using the Methodological Index for Non-Randomized Studies tool. RESULTS Nine retrospective studies including 994 patients were analyzed. Pooled mean overall survival was 10.98 months (95% confidence interval: 8.46-13.50), and progression-free survival was 3.41 months (95% confidence interval: 2.92-3.90). Subgroup overall survival was 12.99 months for lenvatinib, 10.56 months for sorafenib, and 8.79 months for cabozantinib. Objective response rate was 9% and disease control rate 66% by Response Evaluation Criteria in Solid Tumors 1.1 criteria, increasing to 28% and 69% by modified Response Evaluation Criteria in Solid Tumors criteria. Common adverse events included fatigue (52%), elevated liver enzymes (42%), hyperbilirubinemia (38%), anorexia (38%), proteinuria (30%), hand-foot syndrome (34%), and hypertension (18%). Grade 3 or higher events were uncommon, including liver enzyme elevation (9%), proteinuria (15%), hyperbilirubinemia (4%), thrombocytopenia (3%), diarrhea (2%), and hypertension (3%). CONCLUSION TKIs demonstrate modest efficacy and acceptable safety following progression on ATE-BEV, supporting their role in second-line management of advanced HCC, pending further prospective validation.
Zitieren
APA
Montecino, R. B., Rodriguez, N. G., Coreas, N., Mendoza-Quispe, D., Kilani, Y., Kamal, S. A. F., Qureshi, K., & Richart, J. M. (2026). Tyrosine kinase inhibitors after progression on atezolizumab-bevacizumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis. World Journal of Hepatology, 18(6). https://doi.org/10.4254/wjh.121656
Vancouver
Montecino RB, Rodriguez NG, Coreas N, Mendoza-Quispe D, Kilani Y, Kamal SAF, et al. Tyrosine kinase inhibitors after progression on atezolizumab-bevacizumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis. World Journal of Hepatology. 2026;18(6). doi:10.4254/wjh.121656
BibTeX
@article{Montecino2026,
author = {Montecino, Ronald Blanco and Rodriguez, Nehemias Guevara and Coreas, Noemy and Mendoza-Quispe, Daniel and Kilani, Yassine and Kamal, Syeda Ashna Fatima and Qureshi, Kamran and Richart, John M},
title = {Tyrosine kinase inhibitors after progression on atezolizumab-bevacizumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis},
journal = {World Journal of Hepatology},
year = {2026},
volume = {18},
number = {6},
doi = {10.4254/wjh.121656}
}
EUVIMED